ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,744.81
-0.01%
Dow Jones
42,417.41
0.57%
US Dollar vs MXN
19.67001
0.24%
Brent Oil
71.425
0.67%
Bitcoin
66,206.66
1.56%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) Noticias

LXRX

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LXRX
FechaHoraFuenteTítuloSímboloCompañía
27/09/202407:00GlobeNewswire Inc.Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical CongressNASDAQ:LXRXLexicon Pharmaceuticals Inc
16/09/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals Announces Departure of President and Chief Operating OfficerNASDAQ:LXRXLexicon Pharmaceuticals Inc
16/09/202405:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
10/09/202407:00GlobeNewswire Inc.New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/09/202415:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in Upcoming September Investor ConferencesNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/09/202407:00GlobeNewswire Inc.New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes DurationNASDAQ:LXRXLexicon Pharmaceuticals Inc
15/08/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LXRXLexicon Pharmaceuticals Inc
15/08/202415:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
13/08/202407:30GlobeNewswire Inc.Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial PortfolioNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/08/202407:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/08/202407:39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
07/08/202407:00GlobeNewswire Inc.Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education SpecialistsNASDAQ:LXRXLexicon Pharmaceuticals Inc
02/08/202408:37Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LXRXLexicon Pharmaceuticals Inc
02/08/202406:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
01/08/202415:00GlobeNewswire Inc.Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/07/202416:44Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
25/07/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
16/07/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA ResubmissionNASDAQ:LXRXLexicon Pharmaceuticals Inc
15/07/202407:00GlobeNewswire Inc.New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/07/202408:15GlobeNewswire Inc.Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and DirectorNASDAQ:LXRXLexicon Pharmaceuticals Inc
21/06/202407:00GlobeNewswire Inc.Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
19/06/202407:00GlobeNewswire Inc.Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes AssociationNASDAQ:LXRXLexicon Pharmaceuticals Inc
18/06/202407:00GlobeNewswire Inc.Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of CardiologyNASDAQ:LXRXLexicon Pharmaceuticals Inc
14/06/202407:00GlobeNewswire Inc.Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes AssociationNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/05/202406:30GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
14/05/202416:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
14/05/202406:00GlobeNewswire Inc.New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection FractionNASDAQ:LXRXLexicon Pharmaceuticals Inc
10/05/202416:14Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:LXRXLexicon Pharmaceuticals Inc
09/05/202406:30GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
02/05/202415:05GlobeNewswire Inc.Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LXRX

Su Consulta Reciente

TSX
5834
SBI Leasing Services
AMEX
CGDV
Capital Group Dividend V...
COIN
PSBGBP
TSXV
OBI.H
NASDAQ
FWKDRX
Global Bond Income Close...
EU
BRAMC
Regiao Autnoma da Madeir...
LSE
SC28
Roy.bk.can.28
TSXV
MMB.P
TG
45E
Natera
LSE
FQ89
Citi Fun 24
BIT
UC46C4
Unicredit Bank
ASX
SHCDA
BIT
UC170A
Unicredit Bank
USOTC
KEYUF
Keyera (PK)
LSE
GB92
Nationwde. 32
AMEX
RISN
Inspire Tactical Balance...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados